NGX6 gene combined with cisplatin in treatment of lung cancer in vitro and in vivo
- VernacularTitle:NGX6基因联合顺铂治疗肺癌的体内外研究
- Author:
Jing ZHANG
;
Zhe WANG
;
Xiaoyu SHI
;
Wei MENG
;
Feng MA
;
Jin WANG
;
Yongming ZHAO
- Publication Type:Journal Article
- Keywords:
NGX6;
lung cancer;
cisplatin;
A549 cells;
NCI-H1975 cells;
in vitro;
in vivo
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;37(5):33-36
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of NGX6 combined with cisplatin on the inhibition rate of A549 cells and NCI-H1975 cells and antitumor effects in vivo.Methods The NGX6 was loaded in the LPD, and prepare Liposome protamine DNA complexes.A549 cells and NCI-H1975 cells were seperately divided into NGX6 group ( 30 μg/mL NGX6 concentration ) , cisplatin group, NGX6 +cisplatin group, PBS as negative control group.The effect of cytotoxicity of four group on A549 cells and NCI-H1975 cell were evaluated by MTT assay.the clone forming rate and the inhibition rate were determined by Cell colony count.lung transplantation tumor model were successfully established, then nude mice were divided into four groups as abeve, each group of 10, tumor size and survival period were determined tumor cell apoptosis were observed.Results The cell viability of A549 cells and NCI-H1975 cells of (NGX6 +cisplatin) were lower than that of NGX6 group, cisplatin group and saline group, respectively(P<0.01).The cloning efficiency of A549 cells and NCI-H1975 cells of ( NGX6 +cisplatin) were lower than that of NGX6 group, cisplatin group and saline group, respectively(P<0.01).The tumor inhibitory rate was in vivo for (NGX6 +cisplatin) was higher than other group(P<0.01).The median survival of nude mice in (NGX6 +cisplatin), NGX6, cisplatin and saline group were 43,31,29 and 15 days.Conclusion NGX6 combination with cisplatin can inhibit the cell proliferate of lung cancer cells and inhibit the tumor growth and the combination of NGX6 and cisplatin may be a potentially effective treatment for lung cancer.
